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Abstract 
Objective: This study piloted a European technical protocol for conducting chronic hepatitis C prevalence surveys in 
the general population. The pilot study took place in the Bulgarian city of Stara Zagora in 2018, and results of setting 
up, conducting and evaluating the survey are presented.
Results: A probability‑based sample of the general adult population was drawn from the local population registry, 
stratified by age and sex. A sample size of 999 was calculated, and accounting for 50% non‑response, 1998 registered 
invitation letters were sent. Venous blood samples and questionnaire data were collected by the Regional Health 
Inspectorate in Stara Zagora. Blood samples were tested for anti‑HCV, and if reactive for RNA. 252 (21.6%) of the 
participants were included in the study. Mean age and sex distribution differed between the participants (55.9 years, 
60.3% females) and the total sample (48.9 years, 53.4%). The weighted chronic HCV prevalence among participants 
was 0.9% [95% CI 0.2–4.2%]. The approach of only sending registered letters contributed to a low response rate, and 
more efforts are needed to reduce non‑response, especially among men and younger age groups. Results of the 
evaluation were integrated in the final technical protocol.
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Introduction
The World Health Organization global strategy on viral 
hepatitis calls for elimination as a public health threat by 
2030 [1] and national prevalence of chronic hepatitis C 
virus (HCV) infection is one of ten core indicators to be 
monitored [2].
HCV is primarily transmitted through infected blood 
and in European Union (EU) countries it mainly affects 
people who inject drugs (PWID) [3]. However, a higher 
prevalence may be found in birth cohorts of the general 
population (GP) exposed through nosocomial or transfu-
sion-related transmission [4–7].
A recent systematic review found an anti-HCV preva-
lence in the GP in EU/European Economic Area (EEA) 
ranging from 0.1% (Belgium, Ireland and the Nether-
lands) to 5.9% (Italy) [3, 8]. Differences in prevalence 
between 16 countries with available estimates were dif-
ficult to interpret due to heterogeneous methodological 
approaches [3]. To address this, the European Center for 
Disease Prevention and Control contracted the Robert 
Koch Institute (RKI) from 2016 to 2019 to develop and 
pilot an evidence-based technical protocol with the aim 
to contribute to the standardisation of chronic HCV 
prevalence surveys in the GP. The protocol was devel-
oped in conjunction with an international and interdis-
ciplinary expert panel and was published in March 2020 
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[9]. The stand-alone survey approach is one of three rec-
ommended approaches in the technical protocol and was 
piloted in the city of Stara Zagora, Bulgaria.
Stara Zagora is the sixth largest city in Bulgaria with 
an adult population of 120,849.1   The city has one of the 
country’s best economies [10]. Stara Zagora was selected 
as study site because of a strong collaboration between 
the Regional Health Inspectorate (RHI) and the Ministry 
of Health and a good laboratory testing infrastructure.
Robust data on HCV prevalence in Bulgaria are lim-
ited. One multi-centre study (1999–2000) among healthy 
volunteers in the five largest cities found an overall anti-
HCV prevalence of 1.3% with a range from 1.1% in Stara 
Zagora and Plovdiv to 1.6% in Sofia [11]. Another study 
(2010–2011), found an 0.7% anti-HCV prevalence among 
outpatients in the Plovdiv Region [12].
This paper presents the results of the HCV prevalence 
pilot survey and reports on the feasibility of the protocol 
and key lessons learnt.
Methods
A cross-sectional survey was undertaken to measure the 
chronic HCV prevalence (anti-HCV and RNA positive) 
in the adult GP (≥ 18 years) in Stara Zagora.
Sampling
Based on an expected chronic HCV prevalence of 1% and 
a lower precision bound of 0.25%, a sample size of 999 
was calculated. Accounting for an expected non-response 
rate of 50%, the total sample size was 1998.
A probability-based sample of the GP with current 
address in Stara Zagora, stratified by sex and six age 
groups (18–29, 30–39, 40–49, 50–59, 60–69, 70 + years), 
was drawn from the local population registry “Esgraon-
TDS” [13, 14].
Recruitment
Registered invitation letters (Additional file 1: S1a) were 
sent from the local population registry to the invitees. 
The first batch (400 letters) was sent two weeks prior to 
onset of data collection (05.09.2018). A reminder let-
ter followed if no response within three weeks of send-
ing the first letter (Additional file 2: S1b). If people were 
not home when the letter arrived, a note was delivered 
informing of the letter available to be collected at the 
local postal office.
The letters described the aims of the survey, selection 
of participants, opening hours and contact details of the 
study site and the availability of a mobile unit which could 
facilitate participation close to home and the incentive 
(coffee mug and pen) provided after participation. Volun-
tary participation, anonymity and confidentiality of data 
were underlined. A participant information leaflet (Addi-
tional file  3: S2) accompanied the letter providing more 
details about HCV, the survey, the importance of taking 
part, and that test results would be provided followed by 
linkage to care if HCV positive.
A local awareness campaign including posters in phar-
macies and medical centers, announcements on RHI 
Facebook page and local press conferences to encourage 
participation was launched.
Ethical approval, data protection
Persons in the sample were assigned an identification 
number and all identifiable information was kept at the 
local population registry. Participants provided written 
informed consent. Original data were kept at the RHI 
and copies were sent to RKI via an online server allow-
ing an encrypted secure transfer. The survey protocol was 
approved by the local ethics committee established at the 
RHI.
Data collection
Data were collected from 5 September to 16 November 
2018, Monday–Friday: 8:30  am–7:00  pm and Saturday: 
8:30 am–1:30 pm at the RHI, and on Saturdays also in a 
mobile unit.
On site, participants self-completed a questionnaire 
on socio-demographics, HCV testing history, knowledge 
of HCV status and risk factors. Basic sociodemographic 
information on non-responders who called to decline 
participation was collected over the phone.
Venous blood samples were tested for HCV antibod-
ies [Bioelisa, antibody HCV 4th generation (by Biokit)] 
at the RHI laboratory. Anti-HCV reactive samples were 
tested for RNA (Additional file  4. S3) (HCV Real Time 
PCR, Abbott, USA) at the National Reference Laboratory 
“Hepatitis viruses”, Sofia. RNA negative samples were 
tested by immunoblot (Inno-Lia HCV score, Fujirebio, 
Belgium) to confirm the positive anti-HCV result.
During a face-to-face consultation at the RHI a medi-
cal doctor informed participants about their test results. 
Those with chronic HCV were referred to a gastroenter-
ologist in the hospital of Stara Zagora where liver func-
tion was assessed and treatment initiated in line with 
national guidelines.
Data analysis
Double data entry was performed using EpiData (version 
4.4.2.1), and analyses in STATA 15. Descriptive analysis 
was performed for all variables. T-test was used to com-
pare the mean age among the participants and the total 
1 Registered as currently living in Stara Zagora as of 15 March 2018 (Informa-
tion from the Local Population Registry, “Esgraon-TDS”, in Stara Zagora)
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sample, and chi-squared test was used for sex with the 
statistical significance defined as p value < 0.05. Chronic 
HCV prevalence was calculated as crude and weighted 
estimates with 95% confidence intervals (CI). For the lat-
ter, we applied post-stratification weights according to 
age and sex to adjust for non-response.
Evaluation of the draft technical protocol
Indicators were developed and transformed into a ques-
tionnaire with 10 main questions covering objectives of 
the survey, methodology, time, structure, coordination 
and collaboration, ethical approval, data protection, staff 
and budget to be completed by the RHI study team. Dur-
ing a 2  day evaluation workshop recommendations for 
improvement of the protocol were discussed with 14 sur-
vey staff members.
Results
Of 1998 invited people, 1166 received the invitation letter 
of which 252 participated (21.6%) (Fig. 1).
Of the 832 who did not receive the letter, two were 
deceased. The rest did either not pick up the letter or 
were registered with a wrong address.
Non‑participation analysis
Among 170 declining participation, 155 (91.2%) provided 
reasons for non-participation (Table 1).
The age and sex distribution among participants dif-
fered significantly from the total sample (n = 1998). 
The mean age for participants was 55.9  years versus 
48.9 years for the total sample (p < 0.0001). There were 
60.3% females among participants versus 53.4% in the 
total sample (p < 0.0001) (Additional file 4: S3).
Survey participants characteristics
Participants’ mean age was 55.9  years (18–95  years) 
(Table 2) (Additional file 4: S3).
Fig. 1 Flowchart of participation
Table 1 Reasons for non-participation
Reason for non‑participation (n = 155) n (%)
Generally dislike surveys 41 (26.5%)
Living abroad 37 (23.9%)
Not interested 27 (17.4%)
No time 26 (16.8%)
Too ill 22 (14.2%)
Live too far away 6 (5.8%)
Known HCV negative 5 (3.2%)
No suitable appointment 2 (1.3%)
Blood donor 2 (1.3%)
Fear of needles 2 (1.3%)
Got tested in 2018 1 (0.6%)
Known HCV positive 0 (0%)
Do not wish to provide a reason 2 (1.3%)
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Prevalence of HCV
Two participants were both anti-HCV and HCV-RNA 
positive, crude chronic HCV prevalence: 0.8% [95% CI 
0.2–3.1%], weighted prevalence: 0.9% [95% CI 0.2–4.2%].
Factors associated with HCV
Among the 252 participants, the most frequently 
reported factors associated with HCV were surgery 
under general anesthesia (64.1%), followed by blood 
transfusion before 1992 (11.7%) (Additional file  4: S3). 
One of the two HCV positive participants reported hav-
ing injected drugs, the other did not report any known 
factors associated with HCV.
Results from the evaluation
Sufficient staff training was provided and the proto-
col was evaluated as useful and understandable. The 
extended opening hours helped accommodate participa-
tion of people who work, whereas the mobile unit was 
less utilised. Planning took more time than expected (one 
full-time equivalent staff for nine months) particularly on 
administrative tasks and data protection issues. In total, 
19 RHI staff were involved in the data collection.
Discussion
We performed a cross-sectional survey with the aim to 
pilot the draft technical protocol, assess its feasibility 
and to generate an HCV prevalence estimate in the GP 
of Stara Zagora. As the Data Protection Commission 
denied RHI access to contact information for the invited 
participants, the initially planned recruitment strategy 
(involving house-visits to non-responders) was changed, 
allowing only recruitment via letters which resulted in 
not reaching the calculated sample size (n = 999). As 
consequence a low precision for the HCV prevalence 
estimate, for which reason weighting was performed to 
adjust for non-response. The prevalence may under- or 
overestimate the true prevalence due to the failure of 
including persons less likely to participate. Low par-
ticipation and selective non-participation cause bias to 
survey results [15, 16]. Lower socio-economic status, a 
poorer health profile and higher mortality have previ-
ously been found among non-participants compared to 
participants [17, 18]. In this survey, non-participation 
was more frequent among men and younger age groups. 
Higher participation among women and older age groups 
corresponds with findings from other similar surveys 
[19]. Reasons for non-response are likely multifaceted, 
and may differ depending on sex and age group.
Of the 170 people who actively declined participation, 
41 (24%) lived outside Stara Zagora. It is plausible that 
a similar proportion among the 832 who did not receive 
the letter also migrated to other cities or countries e.g. 
for work. This indicates that the sampling frame was not 
up-to-date which is a key requirement for surveys [20].
More efforts are needed to reduce non-participation, 
but their effectiveness may differ between settings [21, 
22]. In a German Health Survey phone calls and house 
visits increased participation from 37 to 49%, with 
greater effect among younger persons, males and non-
Germans [23]. In Finland, SMS reminders have shown 
a positive effect [24]. We used registered letters allow-
ing monitoring of whether letters were received or not, 
but in Bulgaria registered letters are often associated 
with “bad news” (e.g. fines or unpaid taxes). In addition 
to the inconvenience of collecting the letter at the postal 
office, this may explain why many letters were not picked 
up. Also, recruitment via mobile unit might have worked 
better if addresses had been available to RHI staff ena-
bling them to then proactively visit people.
The incentives provided were well accepted, but dif-
ferent incentives for different age groups might have 
impacted positively on the response rate. In Germany 
gift vouchers work well.2 Some studies have shown that 
monetary incentives are preferred [25] whereas in oth-
ers, participants considered them to impose an unwanted 
commercial feature and undermine confidence in the 
survey [26]. Pre-survey qualitative assessments, e.g. focus 
groups, are recommended to identify the most effective 
measures to increase participation [27].
The HCV prevalence weighted for age and sex was 
0.9% [95% CI 0.2–4.2%], and similar to that found in the 
1999–2000 study among healthy volunteers in Stara Zag-
ora [1.05% (anti-HCV)] [11]. Although non-response bias 
Table 2 Sociodemographic characteristics of  participants 
(n = 252)
Sociodemographic characteristics n (%)
Sex
 Female 152 (60.3%)
 Male 100 (39.7%)
Ethnicity
 Bulgarian 248 (98.8%)
 Roma 2 (0.8%)
 Other 1 (0.4%)
 Missing 1 (0.4%)
Highest level of education
 Elementary education 1 (0.4%)
 Primaryeducation 11 (4.4%)
 Secondary education 122 (48.4%)
 Higher education 118 (46.8%)
2 Dr. Antje Gößwald, RKI, personal communication, April 2, 2019
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cannot be ruled out, the use of weights likely reduced 
non-response bias.
Two thirds of participants reported having been 
exposed to risk factors for HCV infection, with surgery 
under general anesthesia being reported by two thirds of 
participants. Nosocomial transmission was the second 
most common transmission-route among acute HCV 
cases in 2017 in the EU/EEA (17%) [28]. In Bulgaria, 
recipients of a transfusion of unscreened blood (prior to 
1992) are a key risk group. Recent reports of breaches of 
infection control procedures also indicate that iatrogenic 
transmission may be a current risk factor for HCV in 
Bulgaria [29, 30], however in our sample, even in those 
reporting potential exposure, none tested positive for 
HCV. Two participants reported injecting drug use, and 
one of them tested HCV positive. The highest rates of 
chronic HCV prevalence in Europe are found among 
PWID ranging from 13.8 to 84.3% (anti-HCV) [31]. Stud-
ies in Bulgaria have found high levels of HCV transmis-
sion among PWID and other groups [32], with one study 
in Sofia reporting 73.9% of 773 PWID being anti-HCV 
positive [33]. GP surveys are not ideal to collect repre-
sentative data on PWID. Other recruitment strategies are 
needed for this vulnerable population [34].
Self-reported data may be prone to social-desirability 
bias. Questions about drug use, imprisonment and pre-
vious test results are sensitive and people may tend to 
provide answers perceived as more socially acceptable. 
Social-desirability bias however is often reduced when 
the questionnaire is self-administered [35]. Recall bias 
might also have played a role in this survey.
Our survey methodology was found to be feasible, 
understandable and helpful in providing a step-by-step 
approach on how to implement a HCV prevalence sur-
vey in the GP. Despite the low response rate, the survey 
approach was found to be useful in estimating the prev-
alence but also resource intensive in terms of time, staff 
and costs. All lessons learnt were included in the final 
version of the technical protocol [9].
The technical protocol targets the GP [9], and estimat-
ing the prevalence among the GP is one step needed to 
estimate the overall national HCV burden. The technical 
protocol provides an opportunity to improve the avail-
ability of reliable and robust data to describe the HCV 
epidemiology and contribute to monitoring progress 
towards the elimination of viral hepatitis.
Limitations
The main limitation in this study is the low response rate 
which reduced the reliability and validity of the results. 
Therefore, we cannot draw conclusions regarding HCV 
prevalence in the GP in Stara Zagora.
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